经皮经股动脉植入药盒治疗晚期原发性肝癌的临床疗效

目的探讨药盒在晚期原发性肝癌治疗中的临床价值。方法无外科手术及动脉栓塞指征的８２例晚期原发性肝癌,依据动脉内化疗方式不同,分为两组：Ａ组４２例,采取经皮经股动脉植入药盒,术后经药盒１周或２周化疗１次;Ｂ组４０例,采取每个月１次插管大剂量化疗。结果Ａ、Ｂ两组有效率（ＣＲ＋ＰＲ）分别为３８．１％和１５．０％（Ｐ＜０．０５）。Ａ组６个月、１年、２年生存率分别为６１．９％、２８．６％、９．５％;Ｂ组分别为２０％、５％、０％（Ｐ＜０．０１）。Ａ组患者的生存质量明显改善,消化道反应、肝、胆、骨髓毒性均较Ｂ组低。结论经药盒间断性化疗并配合地塞米松治疗晚期原发性肝癌可明显改善患者的生存质量,提高生存率。

Percutaneous transfemoral arterial implantation of drug delivery system for arterial infusion therapy of advanced primary hepatic carcinoma

Objective To study the efficiency of arterial infusion chemotherapy via drug delivery system (DDS) for advanced primary hepatic carcinoma.Methods Hepatic arterial infusion chemotherapy was perfomed in 82 cases of primary hepatic carcinoma with no indication for operation or transarterial embolism treatment. The patients were divided into 2 group as follows: (1) Group A: 42 patients were treated intra arterially once every 1 or 2 weeks via implanted DDS. (2) Group B: 40 patients were treated through one bolus arterial infusion chemotherapy, once every month. Results The response rate (CR PR) was 38.1% and 15.0% respectively in group A and B ( P <0.05); the 0.5-,1- and 2- year survival rate was 61.9%, 28.6% and 9.5% respectively in group A, but 20%, 5%, 0% respectively in group B ( P <0.01); Liver, biliary, gastrointestinal and bone marrow toxicity in group A patients was greatly lower than those in group B patients. Conclusion Intermittent arterial infusion chemotherapy via DDS significantly improves survival and quality of life in patients with advanced primary hepatic carcinoma.